The global orthobiologics market is expected to witness strong growth in the years to come due to rising prevalence of musculoskeletal and orthopedic illnesses across the world. Increasing road accidents and sports injuries are likely to increase the product demand in the coming years. In addition, growing geriatric population is a key driving factor in the market as they are more vulnerable to spinal and other orthopedic disorders. This has, in turn, increased the number of orthopedic procedures.
Advancements in implant techniques and rising demand for biological solutions over mechanical solutions are likely to create opportunities for the market. Technological advancements in biomaterials, which are utilized in the production of orthobiologics, are anticipated to support market growth. Such advancements include development of recombinant biologic agents, modifications in graft designs, stem cell therapy, and cultured tissue scaffolds. These innovations are likely to provide benefits, such as smaller incisions, improved biocompatibility, and reduced procedure time. Reduction in post-operative complications using these innovative solutions is expected to boost market growth in the years to come. Furthermore, increasing prevalence of obesity and arthritis, especially in developed countries is expected to boost market growth. This has, in turn, increased the demand for minimally invasive surgeries that generally include bone grafting and growth factor treatments. Orthobiologic therapy is one of the key components of regenerative medicine that are used to treat musculoskeletal diseases, including degenerative osteoarthritis. It is one of the important treatment options for early osteoarthritis (OA) of the knee.
However, strict regulatory framework regarding approval of orthobiologics and high cost of these products are anticipated to challenge the market.
Orthobiologics include a wide range of products, such as bone matrix (DBM), allograft, synthetic bone substitutes, bone morphogenetic protein (BMP), stem cell therapy, and viscosupplementation. Viscosupplementation holds a prominent share in the market due to its high adoption in diseases, such as hip degenerative joint disease and osteoarthritis. Benefits, including fewer side effects, pain reduction, better knee movement, and less-invasive nature, are likely to boost the product’s demand. Moreover, increasing popularity of minimally invasive surgeries is anticipated to boost the segment’s growth in the coming years. Orthobiologics are extensively used in applications, such as spinal fusion, trauma repair, and reconstructive surgery. Spinal fusion is a leading application in the market due to increasing use of demineralized bone matrices, bone morphogenetic proteins, and autografts and allografts in spinal fusion surgeries. This could be attributed to its ability to speed up the bone healing process and offer high bone stability, facilitating long-term improvement of spinal disorders. It also offers fast stimulation of cells to enable bone formation and avoids hospital stays and repetitive visits. Key end users of orthobiologics include hospitals and orthopedic clinics. Hospital occupies a larger share in the market than clinics due to increasing use of orthobiological products in various spinal and reconstructive surgeries conducted in hospitals.
North America is one of the leading regional markets due to presence of key players involved in undertaking new product development strategies. In addition, availability of better compensation policies for soft tissue healing and fusion improvement products is boosting regional market growth.
Asia Pacific is projected to witness strong growth in the years to come owing to rising healthcare expenditure and improving economic conditions. Additionally, increasing awareness regarding availability of these products among physicians is likely to increase their sales. Frequent product launch and improvement in healthcare infrastructure are also projected to offer remunerative gains in the years to come.
Some of the key players operating in the orthobiologics market are DePuy Synthes, Inc.; Medtronic; Stryker Corporation; Genzyme; and Smith & Nephew plc. Players are increasingly investing in R&D activities and taking up strategies, such as mergers and acquisitions, to gain a competitive edge in the market. Moreover, increasing collaborations between biotechnology and medical device companies for the development of effective orthobiologics is expected to support market growth.
For instance, BONESUPPORT, a prominent company in orthobiologics for the management of bone voids, announced that it has started selling CERAMENT BVF through its own US distributor network. Similarly, Cesca Therapeutics Inc. announced that its subsidiary named ThermoGenesis, introduced its PXP System. The system offers fast processing of autologous bone marrow cells in the point-of-care (POC) setting.
